Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Illumina, Inc. announced a definitive agreement to acquire SomaLogic, a leader in data-driven proteomics technology, for $350 million in cash plus up to $75 million in performance-based milestones and royalties, subject to regulatory approvals and expected to close in the first half of 2026.